FDA Warns South Korean Drugmaker for Multiple CGMP Failures

Drug Industry Daily
A A
South Korean OTC drug manufacturer Enprani drew a warning letter from the FDA for CGMP violations observed by FDA investigators at its Incheon facility — including the release of products for sale in the U.S. without checking the identity and strength of their active ingredients.

To View This Article:

Login

Subscribe To Drug Industry Daily